![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » TEIJIN PHARMA, SATO PHARMACEUTICAL JOINTLY INTRODUCE ANTIPSORIATIC AGENT BONALFA
TEIJIN PHARMA, SATO PHARMACEUTICAL JOINTLY INTRODUCE ANTIPSORIATIC AGENT BONALFA
June 26, 2006
Teijin Pharma and Sato Pharmaceutical jointly announced on June 26 that they will begin marketing Bonalfa High Lotion 20 mu-g/g (tacalcitol), an ethical agent for treating psoriasis vulgaris, on June 27.
JCN Network (http://www.japancorp.net/Article.Asp?Art_ID=12772)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct